Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463573) titled 'QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma' on March 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Qilu Pharmaceutical Co., Ltd.
Condition:
Esophageal Squamous Cell Carcinoma (ESCC)
Intervention:
Drug: QLC5508
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: April 5, 2026
Target Sample Size: 466
To know more, visit https://clinicaltrials.gov/study/NCT07...